Pfizer Inc. (NYSE: PFE) has received marketing authorization from the European Commission (EC) for HYMPAVZI™ (marstacimab) for the routine prevention of bleeding episodes in patients aged 12 years and older,…
Eisai Co., Ltd. has announced the launch of TASFYGO® Tablets 35mg (generic name: tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer harboring FGFR2 gene…
Bio-Techne Corporation (NASDAQ: TECH), a leading global provider of innovative tools and bioactive reagents for research and clinical diagnostics, has announced a strategic partnership with Leader Life Sciences. Under this…
On World Children’s Day, the Global Accelerator for Paediatric Formulations Network (GAP-f) highlighted the urgent need for better access to essential medicines for children, particularly in low-resource settings. Despite their…
On Wednesday, November 20, the UN Climate Conference (COP29) in Baku, Azerbaijan, spotlighted urbanization and transportation as critical areas for climate action. The day emphasized the pivotal role of cities…
Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Ziihera® (zanidatamab-hrii) 50mg/mL injection. This intravenous treatment is for adults with previously…
CVS Health is the first healthcare company to receive Health Equity accreditation from URAC, recognizing the work done through CVS Caremark and CVS Specialty. URAC sets high standards in healthcare…
Novartis has secured the top spot in the 2024 Access to Medicine Index (ATMI), highlighting the company’s leadership in enhancing global access to medicines. The Access to Medicine Index, published…
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial, which assessed the noninferiority of subcutaneous pembrolizumab,…
Bayer and Cytokinetics, Inc. (Nasdaq: CYTK) have announced a collaboration and license agreement for the exclusive development and commercialization of aficamten in Japan. Aficamten is a cardiac myosin inhibitor being…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., has announced a settlement agreement with MSN Pharmaceuticals,…
Astellas Pharma Inc. (TSE: 4503) announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on November 15, 2024, regarding the supplemental New Drug Application…